Regulation of glucose/lipid metabolism and insulin sensitivity by interleukin-4

International Journal of Obesity

Volumn 36, Issue 7, 2012, Pages 993-998

  Chang, Y H ^a,b   Ho, K T ^c   Lu, S H ^b   Huang, C N ^b,d   Shiau, M Y ^e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

glucose lipid metabolism; insulin sensitivity; interleukin 4; type 2 diabetes mellitus

Indexed keywords

ADENOVIRUS VECTOR; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 4; PROTEIN KINASE B; RECOMBINANT INTERLEUKIN 4;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-4; LIPID METABOLISM; MICE; MICE, INBRED C57BL; OBESITY;

ADENOVIRIDAE; MUS;

EID: 84862338510     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.168     Document Type: Article

References (42)

1. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 3G-10G.
2. Sone H, Suzuki H, Takahashi A, Yamada N. Disease model: hyperinsulinemia and insulin resistance. Part A-targeted disruption of insulin signaling or glucose transport. Trends Mol Med 2001; 7: 320-322.
3. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
4. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-823.
5. Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med 2004; 21: 203-207.
6. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
7. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-198.
8. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248.
9. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
10. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788.
11. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
12. Wei LH, Jacobs AT, Morris Jr SM, Minor KD, Mazzocco VR, Freund GG. IL-4 and IL-upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol 2000; 279: C248-C256.
13. Wurster AL, Withers DJ, Uchida T, Wither DJ, Grusby MJ. Stat6 and IRS-2 cooperate in interleukin 4 (IL-4)-induced proliferation and differentiation but are dispensable for IL-4-dependent rescue from apoptosis. Mol Cell Biol 2002; 22: 117-126.
14. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers Jr MG, Glasheen E et al. Role of IRS-2 in insulin and cytokine signaling. Nature 1995; 377: 173-177.
15. Hartman ME, O0Connor JC, Godbout JP, Minor KD, Mazzocco VR, Freund GG. Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus. J Biol Chem 2004; 27: 28045-28050.
16. Ho KT, Shiau MY, Chang YH, Chen CM, Yang SC, Huang CN. Association of IL-4 promoter polymorphisms in Taiwanese patients with type 2 diabetes mellitus. Metabolism 2010; 59: 1717-1722.
17. Luo J, Quan J, Tsai J, Hobensack CK, Sullivan C, Hector R et al. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 1998; 47: 663-668.
18. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett PG, Gadbois TM et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 2000; 49: v1390-v1394.
19. Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 2005; 7: 307-317.
20. Nakamura T, Terajima T, Ogata T, Ueno K, Hashimoto N, Ono K et al. Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozotocin and nicotinamide. Biol Pharm Bull 2006; 29: 1167-1174.
21. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves0-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol 2003; 170: 3522-3527.
22. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2: 845-858.
23. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-3399.
24. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005; 146: 3417-3427.
25. Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008; 322: 1539-1543.
26. Lee YW, Eum SY, Chen KC, Hennig B, Toborek M. Gene expression profile in interleukin-4-stimulated human vascular endothelial cells. Mol Med 2004; 10: 19-27.
27. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 2005; 90: 2282-2289.
28. Dufort FJ, Bleiman BF, Gumina MR, Blair D, Wagner DJ, Roberts MF et al. Cutting edge: IL-4-mediated protection of primary B lymphocytes from apoptosis via Stat6-dependent regulation of glycolytic metabolism. J Immunol 2007; 179: 4953-4957.
29. Plas DR, Thompson CB. Cell metabolism in the regulation of programmed cell death. Trends Endocrinol Metab 2002; 13: 75-78.
30. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011; 331: 1621-1624.
31. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 2001; 21: 5899-5912.
32. Lee SJ, Kim JY, Nogueiras R, Linares JF, Perez-Tilve D, Jung DY et al. PKCfregulated inflammation in the nonhematopoietic compartment is critical for obesity-induced glucose intolerance. Cell Metab 2010; 12: 65-77.
33. Duran A, Rodriguez A, Martin P, Serrano M, Flores JM, Leitges M et al. Crosstalk between PKCzeta and the IL4/Stat6 pathway during T-cell-mediated hepatitis. EMBO J 2004; 23: 4595-4605.
34. Martin P, Villares R, Rodriguez-Mascarenhas S, Zaballos A, Leitges M, Kovac J et al. Control of T helper 2 cell function and allergic airway inflammation by PKCzeta. Proc Natl Acad Sci USA 2005; 102: 9866-9871.
35. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesityinduced insulin resistance. Cell Metab 2008; 7: 496-507.
36. Barnea M, Madar Z, Froy O. High-fat diet delays and fasting advances the circadian expression of adiponectin signaling components in mouse liver. Endocrinology 2009; 150: 161-168.
37. Konturek PC, Jaworek J, Maniatoglou A, Bonior J, Meixner H, Konturek SJ et al. Leptin modulates the inflammatory response in acute pancreatitis. Digestion 2002; 65: 149-160.
38. Bełtowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 2003; 9: RA55-RA61.
39. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
40. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
41. Elbe-Bu rger A, Egyed A, Olt S, Klubal R, Mann U, Rappersberger K et al. Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol 2002; 118: 767-778.
42. Nunez NP, Oh WJ, Rozenberg J, Perella C, Anver M, Barrett JC et al. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res 2006; 66: 5469-5476.